Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism LILRB2 inhibitors(Leukocyte immunoglobulin-like receptor subfamily B member 2 inhibitors), LILRB4 inhibitors(Leukocyte immunoglobulin-like receptor subfamily B member 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 22 Mar 2024 |